FTSE fledgling Phytopharm yesterday announced that a drug which originates from a traditional Chinese herbal remedy may provide hope for those suffering from motor neuron disease.
The drug development company said that early-stage tests in laboratory animals showed that the molecule under study, Cogane, had an impact in treating amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, also widely known as Lou Gehrig's disease.
Cogane is already in use against Parkinson's.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
As of 09:18 am shares of Phytopharm are rising by 1.62% to 9.4p.
AB
-
Trump wants to colonise Mars – will it happen?Donald Trump wants to plant the US flag on Mars. Could humans really live there?
-
Klarna postpones US IPO as Trump's tariffs rattle marketsBuy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
